Product Code: BHL2393SS
Introduction to Europe Non-Invasive Prenatal Testing (NIPT) Market
The Europe NIPT market was valued at $859.2 million in 2023 and is expected to reach $3,230.6 million by 2033, registering a CAGR of 14.16% during the forecast period 2023-2033. The European NIPT market is primarily driven by the implementation of favorable guidelines, the inclusion of screening procedures in reimbursement policies, ongoing advancements in technology, expanding commercial opportunities across the region, and the growing preference for non-invasive testing methods.
Market Introduction
| KEY MARKET STATISTICS | |
|---|---|
| Forecast Period | 2023 - 2033 |
| 2023 Evaluation | $859.2 Million |
| 2033 Forecast | $3,230.6 Million |
| CAGR | 14.16% |
The market for non-invasive prenatal testing (NIPT) in Europe has grown significantly in recent years due to the development of genomic technologies and the increased need for prenatal screening techniques that are safer and more accurate. The ground-breaking method known as NIPT looks for chromosomal abnormalities such Patau syndrome, Edwards syndrome, and Down syndrome by analyzing cell-free fetal DNA in the mother's bloodstream. It is a preferred choice for pregnant parents and medical professionals because of its non-invasive nature, which removes the hazards connected to conventional diagnostic techniques like amniocentesis.
Favorable regulatory frameworks, growing patient and healthcare professional knowledge, and the incorporation of NIPT into both public and private healthcare systems all contribute to the market's growth. Its popularity has been further accelerated by reimbursement regulations in a number of European nations, especially in areas with established prenatal care infrastructure.
The market's major players are concentrating on technology advancements to improve the NIPT services' affordability, accessibility, and accuracy. Furthermore, the necessity for trustworthy prenatal screening methods has increased due to the tendency of late pregnancies and the aging of mothers. Consequently, the NIPT market in Europe is expected to increase steadily, contributing to better maternal and fetal healthcare outcomes throughout the area and facilitating informed decision-making.
Market Segmentation:
Segmentation 1: by Application
- Trisomy Detection
- Microdeletion Detection
- Sex Chromosome Aneuploidy Detection
- Others
Segmentation 2: by End User
- Hospitals
- Diagnostic Laboratories
- Others
Segmentation 3: by Platform
- NGS
- PCR
- Others
Segmentation 4: by Method
- cfDNA
- FCMB
Segmentation 5: by Country
- France
- Germany
- Italy
- Spain
- U.K.
- Rest-of-Europe
How can this report add value to an organization?
Workflow/Innovation Strategy: The Europe NIPT market (by application) has been segmented into detailed segments of the application of NIPT based on applications, including trisomy detection, microdeletion detection, sex chromosome aneuploidy detection, and others.
Growth/Marketing Strategy: Constant advancement and innovation to enhance performance and efficiency can enabled prominent players to command premium prices while maintaining growth in revenue and volume.
Competitive Strategy: Key players in the Europe NIPT market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe NIPT market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.
Some prominent names established in this market are:
- F. Hoffmann-La Roche Ltd
- CENTOGENE N.V.
- Yourgene Health
- Eurofins Scientific SE
Table of Contents
Executive Summary
Scope and Definition
1 Markets
- 1.1 Trends: Current and Future Impact Assessment
- 1.1.1 Increasing Strategic Partnerships and Alliances between Market Players
- 1.1.2 Expanding Applications in NIPT Products
- 1.2 Supply Chain Overview
- 1.3 Research and Development Review
- 1.3.1 Patent Filing Trend (by Country, Year)
- 1.4 Regulatory Landscape
- 1.4.1 Regulatory Scenario in the U.K.
- 1.4.2 Regulatory Scenario in Germany
- 1.4.3 Regulatory Scenario in France
- 1.4.4 Regulatory Scenario in Spain
- 1.4.5 Regulatory Scenario in Italy
- 1.4.6 Regulatory Scenario in the Netherlands
- 1.5 Reimbursement Scenario
- 1.6 Market Dynamics Overview
- 1.6.1 Market Drivers
- 1.6.1.1 High Incidence of Genetic Disorders
- 1.6.1.2 Rising Maternal Age
- 1.6.1.3 Increasing Number of Reimbursement Policies toward Genetic Coverage
- 1.6.1.4 Increased Emphasis on Early Detection and Prevention
- 1.6.2 Market Restraints
- 1.6.2.1 Stringent Regulatory Guidelines and Ethical Hurdles
- 1.6.2.2 Lack of Awareness Regarding NIPT
- 1.6.2.3 Limitations and Considerations in Non-Invasive Prenatal Testing
- 1.6.3 Market Opportunities
- 1.6.3.1 Increasing Focus on Non-Invasive Pre-Implantation Genetic Testing (niPGT)
- 1.6.1 Market Drivers
2 Regions
- 2.1 Drivers and Restraints
- 2.2 Regional Summary
- 2.3 Europe
- 2.3.1 Regional Overview
- 2.3.2 Driving Factors for Market Growth
- 2.3.3 Factors Challenging the Market
- 2.3.4 Application
- 2.3.5 Product
- 2.3.6 France
- 2.3.7 Germany
- 2.3.8 U.K.
- 2.3.9 Spain
- 2.3.10 Italy
- 2.3.11 Rest-of-Europe
3 Markets - Competitive Benchmarking & Company Profiles
- 3.1 Competitive Landscape
- 3.1.1 F. Hoffmann-La Roche Ltd
- 3.1.1.1 Overview
- 3.1.1.2 Product Portfolio
- 3.1.1.3 Top Competitors
- 3.1.1.4 Target Customers
- 3.1.1.5 Key Personnel
- 3.1.1.6 Analyst View
- 3.1.2 CENTOGENE N.V.
- 3.1.2.1 Overview
- 3.1.2.2 Product Portfolio
- 3.1.2.3 Top Competitors
- 3.1.2.4 Target Customers
- 3.1.2.5 Key Personnel
- 3.1.2.6 Analyst View
- 3.1.3 Yourgene Health
- 3.1.3.1 Overview
- 3.1.3.2 Product Portfolio
- 3.1.3.3 Top Competitors
- 3.1.3.4 Target Customers
- 3.1.3.5 Key Personnel
- 3.1.3.6 Analyst View
- 3.1.4 Eurofins Scientific SE
- 3.1.4.1 Overview
- 3.1.4.2 Product Portfolio
- 3.1.4.3 Top Competitors
- 3.1.4.4 Target Customers
- 3.1.4.5 Key Personnel
- 3.1.4.6 Analyst View
- 3.1.1 F. Hoffmann-La Roche Ltd
4 Research Methodology
- 4.1 Data Sources
- 4.1.1 Primary Data Sources
- 4.1.2 Secondary Data Sources
- 4.1.3 Data Triangulation
- 4.2 Market Estimation and Forecast
